Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Mendota Financial Group LLC

Mendota Financial Group LLC trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 18.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,222 shares of the medical equipment provider’s stock after selling 282 shares during the period. Mendota Financial Group LLC’s holdings in Lantheus were worth $109,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. boosted its position in Lantheus by 18.5% during the second quarter. Victory Capital Management Inc. now owns 25,705 shares of the medical equipment provider’s stock worth $2,064,000 after purchasing an additional 4,021 shares in the last quarter. BOKF NA acquired a new stake in Lantheus in the 2nd quarter valued at about $740,000. Federated Hermes Inc. increased its holdings in Lantheus by 9.9% during the 2nd quarter. Federated Hermes Inc. now owns 269,682 shares of the medical equipment provider’s stock valued at $21,653,000 after acquiring an additional 24,326 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Lantheus by 0.3% in the second quarter. Envestnet Asset Management Inc. now owns 111,498 shares of the medical equipment provider’s stock valued at $8,952,000 after purchasing an additional 356 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after purchasing an additional 19,071 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LNTH shares. Truist Financial reaffirmed a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Trading Down 1.3 %

LNTH stock opened at $94.65 on Tuesday. The stock has a 50-day moving average price of $89.98 and a two-hundred day moving average price of $99.78. The company has a market cap of $6.58 billion, a PE ratio of 15.75 and a beta of 0.46. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.